Literature DB >> 11298601

Characterization and localization of expression of an erythropoietin-induced gene, ERIC-1/TACC3, identified in erythroid precursor cells.

P J McKeveney1, V M Hodges, R N Mullan, P Maxwell, D Simpson, A Thompson, P C Winter, T R Lappin, A P Maxwell.   

Abstract

Gene expression profiles during erythropoietin (Epo)-induced differentiation of erythroid progenitor cells derived from the Friend virus anaemia (FVA) and phenylhydrazine (PHZ) murine models have been examined using differential display polymerase chain reaction (PCR). Ten cDNA fragments upregulated by Epo were isolated. The ribonuclease protection assay confirmed differential expression between Epo-stimulated and Epo-deprived cells for one of these, provisionally named ERIC-1. Sequencing of the full-length cDNA predicted a protein of 558 amino acids, 17 amino acids longer than mTACC3, the third member of a novel family of proteins that contain a coiled-coil domain. The human homologue, cloned using rapid amplification of cDNA ends (RACE)-PCR, encodes a larger protein of 838 amino acids that is identical to hTACC3. In addition to erythroid precursor cells, ERIC-1/TACC3 is expressed at high levels in the testes, at moderate levels in the thymus and peripheral leucocytes, and at lower levels in the spleen and intestinal tissue. Immunohistochemical analysis using an antibody to a GST fusion product of the C-terminus of hERIC-1/TACC3 revealed that it is localized to Sertoli cells in the human testes. Confocal microscopy demonstrated hERIC-1/TACC3 protein concentrated in the perinuclear vesicles of dermal microvascular endothelial cells. Although ERIC-1/TACC3 is expressed in a wide range of tissues, its upregulation by Epo in erythroid progenitors implies that it has a role in terminal erythropoiesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11298601     DOI: 10.1046/j.1365-2141.2001.02644.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Coactivators necessary for transcriptional output of the hypoxia inducible factor, HIF, are directly recruited by ARNT PAS-B.

Authors:  Carrie L Partch; Kevin H Gardner
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-21       Impact factor: 11.205

2.  The centrosomal protein TACC3 is essential for hematopoietic stem cell function and genetically interfaces with p53-regulated apoptosis.

Authors:  Roland P Piekorz; Angelika Hoffmeyer; Christopher D Duntsch; Catriona McKay; Hideaki Nakajima; Veronika Sexl; Linda Snyder; Jerold Rehg; James N Ihle
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

3.  Transforming acidic coiled-coil protein-3 (Tacc3) acts as a negative regulator of Notch signaling through binding to CDC10/Ankyrin repeats.

Authors:  Sharon Bargo; Ahmed Raafat; David McCurdy; Idean Amirjazil; Youmin Shu; June Traicoff; Joshua Plant; Barbara K Vonderhaar; Robert Callahan
Journal:  Biochem Biophys Res Commun       Date:  2010-09-06       Impact factor: 3.575

4.  The centrosomal, putative tumor suppressor protein TACC2 is dispensable for normal development, and deficiency does not lead to cancer.

Authors:  Michael M Schuendeln; Roland P Piekorz; Christian Wichmann; Youngsoo Lee; Peter J McKinnon; Kelli Boyd; Yutaka Takahashi; James N Ihle
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

5.  Aberrations of TACC1 and TACC3 are associated with ovarian cancer.

Authors:  Brenda Lauffart; Mary M Vaughan; Roger Eddy; David Chervinsky; Richard A DiCioccio; Jennifer D Black; Ivan H Still
Journal:  BMC Womens Health       Date:  2005-05-26       Impact factor: 2.809

6.  TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters.

Authors:  Tiziana Angrisano; Francesca Lembo; Raffaela Pero; Francesco Natale; Alfredo Fusco; Vittorio E Avvedimento; Carmelo B Bruni; Lorenzo Chiariotti
Journal:  Nucleic Acids Res       Date:  2006-01-12       Impact factor: 16.971

7.  TACC3 promotes colorectal cancer tumourigenesis and correlates with poor prognosis.

Authors:  Yong Du; Lili Liu; Chenliang Wang; Bohua Kuang; Shumei Yan; Aijun Zhou; Chuangyu Wen; Junxiong Chen; Yue Wu; Xiangling Yang; Guokai Feng; Bin Liu; Aikichi Iwamoto; Musheng Zeng; Jianping Wang; Xing Zhang; Huanliang Liu
Journal:  Oncotarget       Date:  2016-07-05

8.  TACC3 as an independent prognostic marker for solid tumors: a systematic review and meta-analysis.

Authors:  June Wang; Shenlin Du; Wei Fan; Ping Wang; Weiqing Yang; Mingxia Yu
Journal:  Oncotarget       Date:  2017-08-24

9.  Pretreatment TACC3 expression in locally advanced rectal cancer decreases the response to neoadjuvant chemoradiotherapy.

Authors:  Wen-Juan Ma; Yang-Kui Gu; Jian-Hong Peng; Xue-Cen Wang; Xin Yue; Zhi-Zhong Pan; Gong Chen; Hai-Neng Xu; Zhong-Guo Zhou; Rong-Xin Zhang
Journal:  Aging (Albany NY)       Date:  2018-10-19       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.